reviewTop 1% cited

The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy

Clinical Cancer Research · 2006 · Vol. 12(18) · pp. 5268–5272

Maurizio Scaltriti✉(Universitat Autònoma de Barcelona)José Baselga(Universitat Autònoma de Barcelona)

Abstract

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is frequently expressed in epithelial tumors. The EGFR was the first receptor to be proposed as a target for cancer therapy, and after 2 decades of intensive research, there are several anti-EGFR agents available in the clinic. Recent advances in our understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clinical targeting of this receptor and may serve as a model for strategies aimed at targeting other receptors.

HER2/EGFR in Cancer Research Lung Cancer Treatments and Mutations Chronic Lymphocytic Leukemia ResearchEpidermal growth factor receptorReceptorCancer researchGrowth factor receptorTyrosine kinaseGrowth factor receptor inhibitorReceptor tyrosine kinaseInsulin-like growth factor 1 receptorROR1Targeted therapy

MeSH terms

HumansModels, BiologicalMutationGenes, rasSignal Transductionsrc-Family KinasesPhosphatidylinositol 3-KinasesExtracellular Signal-Regulated MAP Kinasesraf KinasesSTAT Transcription FactorsOncogene Protein v-aktErbB Receptors

Citations

901

FWCI

19.78

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro